A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

MRG003

Administered intravenously

DRUG

Cetuximab injection

Administered intravenously

DRUG

Methotrexate Injection

Administered intravenously

Trial Locations (1)

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Miracogen Inc.

INDUSTRY

NCT05751512 - A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN | Biotech Hunter | Biotech Hunter